Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB

John Metcalfe, Peter Bacchetti, Roy Gerona, Ali Esmail, Keertan Dheda, Monica Gandhi
ERJ Open Research 2019 5: 00046-2019; DOI: 10.1183/23120541.00046-2019
John Metcalfe
1Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: john.metcalfe@ucsf.edu
Peter Bacchetti
2Dept of Epidemiology and Biostatistics, University of California, UCSF, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roy Gerona
3Maternal-Fetal Medicine Division, Dept of Obstetrics, Gynecology and Reproductive Sciences, University of California, UCSF, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali Esmail
4Lung Infection and Immunity Unit, Division of Pulmonology, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keertan Dheda
4Lung Infection and Immunity Unit, Division of Pulmonology, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monica Gandhi
5Division of HIV, Infectious Diseases and Global Medicine, Dept of Medicine, University of California, UCSF, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Anti-tuberculosis drug concentrations in hair, a non-biohazardous and noninvasively collected biomatrix, predict extensively drug-resistant-TB clinical outcomes in a high-burden setting. http://ow.ly/80xi30o8qSa

Abstract

Therapeutic drug monitoring for drug-resistant tuberculosis (TB) is likely to improve treatment outcomes. While assessments of plasma drug levels can explain pharmacokinetic variability among trial participants, these measures require phlebotomy and a cold chain, and are generally not repeated frequently enough to characterise drug exposure over time. Using a novel multi-analyte assay, we found evidence that higher anti-TB drug concentrations in hair, a non-biohazardous and noninvasively collected biomatrix, predict extensively-drug resistant-TB clinical outcomes in a high-burden setting.

Introduction

In 2017, the World Health Organization estimated that 558 000 individuals developed multidrug-resistant tuberculosis (MDR-TB) [1]. Treatment outcomes remain poor, and result from clinical factors (HIV co-infection, disease severity), poor adherence to complicated regimens, low anti-TB drug concentrations from pharmacokinetic variability, suboptimal treatment regimens, or a combination of these. While assessments of plasma drug levels can explain pharmacokinetic variability among trial participants, these measures require phlebotomy and a cold chain, and are generally not repeated frequently enough to characterise drug exposure over time in real-world programmes. Measuring drug levels in dried blood spots circumvent some of these barriers, including the need for shipping samples via a cold chain, but assays for many MDR-TB drugs in dried blood spots have not been developed. A noninvasive method that does not require phlebotomy skills or biohazard precautions for long-term pharmacologic monitoring of multiple simultaneous MDR-TB drugs, particularly in patients with HIV infection, is likely to significantly advance the clinical management of MDR-TB.

Our group has extensive experience in the monitoring of antiretroviral concentrations in hair samples for patients with HIV, and have found that antiretroviral hair levels display linear relationships with dose within individuals [2], and are strong independent predictors of treatment outcomes [3]. In the field of TB, subtherapeutic concentrations of drugs are common (in particular among patients with MDR-TB [4–6] and those who are HIV co-infected [7–10]) and have been associated with acquired drug resistance [11–16], adverse treatment outcomes in drug-sensitive TB [17–19], increased target size (i.e. number of unique mutations conferring drug resistance) [20], and antagonistic (i.e. less than additive) drug interactions [21]. Furthermore, relative to antiretroviral combinations, TB regimens used for drug-resistant TB treatment are more toxic, less standardised, and may pose even greater challenges for adequate patient adherence [22].

Methods

We hypothesised that anti-TB drug concentrations in hair are associated with clinical outcomes among programmatically treated MDR-TB and extensively drug-resistant (XDR)-TB patients. Between July 1, 2016 and January 1, 2018, small, cosmetically unnoticeable hair samples (20–50 strands) were collected from 47 patients, the majority of whom were undergoing programmatic, inpatient, directly observed treatment for MDR- or XDR-TB at the Brooklyn Chest Hospital (Cape Town, South Africa). Of these, 46 (98%) were female, 31 (66%) were HIV-positive and 30 (64%) had XDR-TB (with the remainder having MDR-TB). Patients were taking a median of five drugs (range 3–7), and the median amount of time on drugs prior to hair sampling was 87 days (interquartile range (IQR) 50–160 days). No participants were taking prothionamide, and only one participant (in a clinical trial) was taking pretomanid.

We analysed isoniazid (INH), ethambutol (EMB), pyrazinamide (PZA), levofloxacin (LFX), moxifloxacin (MFX), linezolid (LZD), clofazimine (CFZ), bedaquiline (BDQ), pretomanid and/or prothionamide in a multi-analyte panel using liquid chromatography/tandem mass spectrometry (LC-MS/MS) developed by our group [23]. Measured drug concentrations in hair are summarised in table 1. We calculated a Z-score for hair concentration of each drug (difference from the mean, divided by the standard deviation), and then averaged these for all drugs for a given participant to obtain their mean anti-TB drug Z-score. Because 3 cm of hair were assayed, representing ∼90 days of hair growth, concentrations of drugs not taken for the entire 90 days before collection were scaled up by a factor of 90/Days, where Days was the number of days prior to collection that the drug was taken; only drugs that the patient was taking at the time of hair collection for at least 14 days were considered. For BDQ and CFZ, a more elaborate adjustment was used because of the long half-life of these drugs. From the first day of drug dosing, the contribution of each dose taken to the systemic plasma concentration during each day in the hair growth window was calculated, assuming rapid absorption of each dose followed by a half-life of 165 days for BDQ and 70 days for CFZ, and these were summed over all 90 days to obtain a total number of dose-days reflected in the hair sample (incorporation of drug into hair was assumed to be proportional to the systemic plasma concentration.) The measured concentrations were then multiplied by 1000/(total dose-days) to adjust for differing amounts of drug taken that should be reflected in the hair samples. Kaplan–Meier methods calculated the time to our a priori primary composite outcome of time from start of regimen to the first occurrence of treatment failure, relapse or death, and a Cox proportional hazards model assessed the effect of mean drug Z-score on this outcome. The levels of each measured drug were evaluated as individual predictors, restricted to those participants who were taking the drug at the time of hair collection and continued taking it until the outcome or the end of follow-up. Because INH, PZA, and CFZ concentrations were strongly right skewed, they were logarithmically transformed before Z-score calculation. Because of potential greater efficacy in the setting of MDR-TB, a secondary predictor combining only BDQ, LZD, MFX, LFX and CFZ (mean Z-score 5) was also assessed. A number of a priori defined two-predictor models were evaluated. Treatment outcome categories conformed to the definitions agreed for use by TB programmes for MDR-/XDR-TB, with the exception of loss to follow-up [24]. Loss to follow-up was a priori excluded from our composite outcome because of the uncertain relationship between sub-therapeutic drug exposure and treatment interruption, and the possibility that supra-therapeutic drug levels (and toxicity) could more plausibly account for an opposing association.

View this table:
  • View inline
  • View popup
TABLE 1

Observed anti-tuberculosis drug concentrations in small hair samples

Results

An overall Kaplan–Meier curve is shown in figure 1. Median follow-up time after hair sampling was 354 days (IQR 43–482 days) among 23 individuals (out of the total sample size of 47) who were continuing treatment (13 were treated as right-censored observations) or who had been lost to follow-up (10 were also censored) by the end of the study. Median follow-up was 206 days (IQR 104–314 days) and 437 days (IQR 413–503 days) among those with a composite poor outcome (11 failure events) and those who were considered microbiologically cured (13 treated as never reaching the outcome), respectively. Univariate proportional hazards regression found suggestive evidence that higher drug concentrations in hair may be substantially associated with lower risk of poor treatment outcome (HR 0.60, 95% CI 0.27–1.34; p=0.21), although this had wide uncertainty and did not reach statistical significance (table 2). Models that control for available covariates are shown in the supplementary material. Controlling for concomitant HIV led to a slightly larger effect size for hair concentration Z-score (HR 0.53), but others led to weaker effects (HR up to 0.71).

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Time from hair sampling to composite outcome of treatment failure, relapse or death. Kaplan–Meier curves shows time to treatment failure, relapse or death among patients treated for multidrug-resistant or extensively drug-resistant-tuberculosis at Brooklyn Chest Hospital (Cape Town, South Africa). Shaded area indicates the ±95% confidence interval for the survival function.

View this table:
  • View inline
  • View popup
TABLE 2

Proportional hazards models for association of hair drug concentrations and time to failure

Discussion

We found preliminary evidence that anti-TB drug concentrations in hair, a novel and noninvasively collected biomatrix, are associated with clinical outcomes for drug-resistant TB among programmatically treated patients. Our panel assay, measuring 11 drugs used in second-line treatment regimens, was tested in scalp hair for individuals on multiple regimens at varying time-points during treatment. Our data suggest variability in hair concentrations for individual drugs likely due to individual pharmacokinetic variability (given that drugs were directly administered by nurses during inpatient treatment), and an effect size, despite not reaching statistical significance, suggesting a strong association between higher hair levels and better clinical outcomes.

Our results have strong biologic plausibility in that low anti-TB drug exposure predisposes to prolonged treatment, treatment failure, relapse and development of drug resistance [11, 25]. Although treatment in our study was directly administered to hospitalised patients, inter-individual pharmacokinetic variability is known to be influenced by body weight, sex, pharmacogenomics, comorbidities including HIV [26] and diabetes mellitus [27], and even drug manufacturer [28]. Despite significant inter-individual variability in drug exposure, as well clinical trials of TB therapeutics demonstrating the importance of pharmacodynamics [29], therapeutic drug monitoring of anti-TB drugs is not routinely employed, mainly due to feasibility issues. Hair collection is noninvasive and does not require phlebotomy skills, sterile equipment, a cold chain or biohazard precautions during collection or shipping, features which enhance feasibility in regions where resistant TB is prevalent.

A unique feature of hair levels relative to blood or urine concentrations is their ability to objectively assess drug exposure over prior weeks to months rather than hours to days [30]. Hair grows remarkably consistently in the occipital region of the scalp at approximately 1 cm per month, which allows hair to serve as a marker of time. The ability to measure average exposure to drugs, rather than assessing a snapshot of exposure via a shorter-term measure that may be influenced by intra-individual pharmacokinetics or adherence variability, is a major strength of therapeutic drug monitoring using hair levels. Moreover, hair can assess exposure over shorter periods of time than assessed in this paper (e.g. 1 month) and can be combined with plasma levels to provide information on patterns of drug exposure. Limitations, however, include that hair cannot be collected from individuals with shaved heads or very short hair, and that certain treatments, notably bleaching, can lower hair drug levels. Moreover, the assays described here require sophisticated equipment (LC-MS/MS), limiting current feasibility to research settings; however, lower cost assays using bench top systems are in development [31].

In conclusion, we provide promising evidence that noninvasive pharmacokinetic monitoring of small hair samples at pre-specified intervals may detect low anti-TB drug exposure in resistant TB infection, which could trigger interventions such as medication switches for drugs with very low levels or identifying drug–drug interactions prior to treatment failure, thereby prolonging regimen durability. As with conventional pharmacokinetic assessments, there is a need for randomised trials to assess the benefits of real-time hair level monitoring in the management of drug-resistant TB.

Supplementary material

Supplementary Material

Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

ERJOR-00046-2019_supplemental_table 00046-2019_supplemental_table

Footnotes

  • This article has supplementary material available from openres.ersjournals.com

  • Conflict of interest: J. Metcalfe reports grants from NIH, during the conduct of the study.

  • Conflict of interest: P. Bacchetti reports grants from NIH, during the conduct of the study.

  • Conflict of interest: R. Gerona reports grants from NIH, during the conduct of the study.

  • Conflict of interest: A. Esmail reports grants from NIH, during the conduct of the study.

  • Conflict of interest: K. Dheda reports grants from NIH, during the conduct of the study.

  • Conflict of interest: M. Gandhi reports grants from NIH, during the conduct of the study.

  • Support statement: Funding for this work was provided by NIH/NIAID R01 AI123024 (principal investigators J. Metcalfe and M. Gandhi). Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received February 28, 2019.
  • Accepted March 5, 2019.
  • Copyright ©ERS 2019
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. World Health Organization
    . Global tuberculosis report 2018. Geneva, World Health Organization, 2018.
  2. ↵
    1. Liu AY,
    2. Yang Q,
    3. Huang Y, et al.
    Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One 2014; 9: e83736.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Gandhi M,
    2. Ofokotun I,
    3. Bacchetti P, et al.
    Antiretroviral concentrations in hair strongly predict virologic response in a large HIV treatment-naive clinical trial. Clin Infect Dis 2019; 68: 1044–1047.
    OpenUrl
  4. ↵
    1. Mpagama SG,
    2. Ndusilo N,
    3. Stroup S, et al.
    Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2014; 58: 782–788.
    OpenUrlAbstract/FREE Full Text
    1. Barroso EC,
    2. Pinheiro VG,
    3. Facanha MC, et al.
    Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis. Am J Trop Med Hyg 2009; 81: 322–329.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Heysell SK,
    2. Moore JL,
    3. Peloquin CA, et al.
    Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in Virginia, 2009–2014. Tuberc Respir Dis (Seoul) 2015; 78: 78–84.
    OpenUrlCrossRefPubMed
  6. ↵
    1. McIlleron H,
    2. Rustomjee R,
    3. Vahedi M, et al.
    Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother 2012; 56: 3232–3238.
    OpenUrlAbstract/FREE Full Text
    1. Daskapan A,
    2. de Lange WC,
    3. Akkerman OW, et al.
    The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection. Eur Respir J 2015; 45: 569–571.
    OpenUrlAbstract/FREE Full Text
    1. Gurumurthy P,
    2. Ramachandran G,
    3. Hemanth Kumar AK, et al.
    Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother 2004; 48: 4473–4475.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Holland DP,
    2. Hamilton CD,
    3. Weintrob AC, et al.
    Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy 2009; 29: 503–510.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Pasipanodya JG,
    2. McIlleron H,
    3. Burger A, et al.
    Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208: 1464–1473.
    OpenUrlCrossRefPubMed
    1. Burman W,
    2. Benator D,
    3. Vernon A, et al.
    Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 2006; 173: 350–356.
    OpenUrlCrossRefPubMed
    1. Vernon A,
    2. Burman W,
    3. Benator D, et al.
    Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353: 1843–1847.
    OpenUrlCrossRefPubMed
    1. Benator D,
    2. Bhattacharya M,
    3. Bozeman L, et al.
    Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360: 528–534.
    OpenUrlCrossRefPubMed
    1. Weiner M,
    2. Benator D,
    3. Burman W, et al.
    Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40: 1481–1491.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Van Tongeren L,
    2. Nolan S,
    3. Cook VJ, et al.
    Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis. Int J Tuberc Lung Dis 2013; 17: 221–224.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Chideya S,
    2. Winston CA,
    3. Peloquin CA, et al.
    Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009; 48: 1685–1694.
    OpenUrlCrossRefPubMed
    1. Weiner M,
    2. Burman W,
    3. Vernon A, et al.
    Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003; 167: 1341–1347.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Prahl JB,
    2. Johansen IS,
    3. Cohen AS, et al.
    Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. J Antimicrob Chemother 2015; 70: 321–322.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Ford CB,
    2. Shah RR,
    3. Maeda MK, et al.
    Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet 2013; 45: 784–790.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Ankomah P,
    2. Levin BR
    . Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum. PLoS Pathog 2012; 8: e1002487.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Daftary A,
    2. Padayatchi N,
    3. O'Donnell M
    . Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa. Glob Public Health 2014; 9: 1107–1116.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Gerona R,
    2. Wen A,
    3. Koss C, et al.
    A multi-analyte panel for non-invasive pharmacokinetic monitoring of second-line anti-tuberculosis drugs. Int J Tuberc Lung Dis 2016; 20: 991–992.
    OpenUrl
  16. ↵
    1. World Health Organization
    . Definitions and reporting framework for tuberculosis – 2013 revision. Geneva, World Health Organization, 2014.
  17. ↵
    1. Sekaggya-Wiltshire C,
    2. von Braun A,
    3. Lamorde M, et al.
    Delayed sputum culture conversion in tuberculosis-human immunodeficiency virus-coinfected patients with low isoniazid and rifampicin concentrations. Clin Infect Dis 2018; 67: 708–716.
    OpenUrlCrossRef
  18. ↵
    1. Daskapan A,
    2. Idrus LR,
    3. Postma MJ, et al.
    A systematic review on the effect of HIV infection on the pharmacokinetics of first-line tuberculosis drugs. Clin Pharmacokinet 2018; [doi: 10.1007/s40262-018-0716-8].
  19. ↵
    1. Alkabab Y,
    2. Keller S,
    3. Dodge D, et al.
    Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA. BMC Infect Dis 2017; 17: 125.
    OpenUrl
  20. ↵
    1. Court R,
    2. Chirehwa MT,
    3. Wiesner L, et al.
    Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications. Int J Tuberc Lung Dis 2018; 22: 537–543.
    OpenUrlCrossRef
  21. ↵
    1. McCallum AD,
    2. Sloan DJ
    . The importance of clinical pharmacokinetic-pharmacodynamic studies in unraveling the determinants of early and late tuberculosis outcomes. Int J Pharmacokinet 2017; 2: 195–212.
    OpenUrl
  22. ↵
    1. Baciu T,
    2. Borrull F,
    3. Aguilar C, et al.
    Recent trends in analytical methods and separation techniques for drugs of abuse in hair. Anal Chim Acta 2015; 856: 1–26.
    OpenUrlPubMed
  23. ↵
    1. Gandhi M,
    2. Yang Q,
    3. Bacchetti P, et al.
    Short communication: a low-cost method for analyzing nevirapine levels in hair as a marker of adherence in resource-limited settings. AIDS Res Hum Retroviruses 2014; 30: 25–28.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Vol 5 Issue 2 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB
John Metcalfe, Peter Bacchetti, Roy Gerona, Ali Esmail, Keertan Dheda, Monica Gandhi
ERJ Open Research Apr 2019, 5 (2) 00046-2019; DOI: 10.1183/23120541.00046-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB
John Metcalfe, Peter Bacchetti, Roy Gerona, Ali Esmail, Keertan Dheda, Monica Gandhi
ERJ Open Research Apr 2019, 5 (2) 00046-2019; DOI: 10.1183/23120541.00046-2019
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original articles

  • Endobronchial autologous BM-MSCs in IPF patients
  • Effect of β-blockers on the risk of COPD exacerbations
  • Recurrence of symptoms after childhood LRTI
Show more Original articles

Tuberculosis

  • Multidrug-resistant tuberculosis in Finland
  • IGRA screening in biologics
  • Prevalence and genetics of FLD resistance of M. tuberculosis
Show more Tuberculosis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society